Search the Newsreel

RCKT (RCKT) insider Martin Wilson plans sale of 3,493 vested shares

Martin Wilson, an insider at ROCKET PHARMACEUTICALS, INC. (RCKT), has filed a Form 144 notice to sell up to 3,493 common shares. These shares originated from a restricted stock vesting event on August 11, 2026, as compensation. The proposed sale is set for August …

Gaurav Shah plans stock sale in RCKT (RCKT) after prior share disposals

Gaurav Shah, an insider at RCKT (Rocket Pharmaceuticals, Inc.), has filed to sell 2,837 shares of common stock through Fidelity Brokerage Services LLC, valued at $9,592.18. This planned sale on August 13, 2026, is related to restricted stock vesting designated as compensation. This follows …

CCORF Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $10

CCORF has reiterated its Buy rating for Rocket Pharmaceuticals (RCKT.US) and maintained a target price of $10. This indicates a continued positive outlook on the company's stock performance by the firm.

Rocket Pharmaceuticals, Inc. expected to post a loss of 42 cents a share - Earnings Preview

Rocket Pharmaceuticals, Inc. is projected to report a loss of 42 cents per share. This information comes from an earnings preview, indicating upcoming financial results for the company.

ROCKET PHARMACEUTICALS, INC. SEC Filing (Aug 11, 2026)

ROCKET PHARMACEUTICALS, INC. filed a Form 144 with the SEC on August 11, 2026, indicating a proposed sale of securities. The filing details the acquisition of 4701 shares of common stock through restricted stock vesting on August 5, 2026, and their intended sale via …

Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals announced its second-quarter 2026 financial results, highlighting the FDA approval of KRESLADI™ and the subsequent sale of its Priority Review Voucher for $180 million. The company also reported positive initial safety findings for RP-A501 in Danon disease and anticipates further clinical and …

Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus

Rocket Pharmaceuticals (RCKT) reported Q2 2026 earnings of $1.08 per share, significantly beating the Zacks Consensus Estimate, contrasting with a loss in the prior year. The company saw reduced general and administrative and R&D expenses. Key updates include the ongoing launch preparations for its …

Rocket Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $8.84, Implies 143% Upside

Rocket Pharmaceuticals, Inc. (RCKT) has seen its average 12-month price target reduced to $8.84 from $9.39 by 11 analysts. Despite the cut, this new target still suggests a significant 143% potential upside based on the Aug. 10 closing price. The consensus rating among 15 …

RCKT Maintains Rating by Wedbush -- Price Target Lowered to $15

Wedbush has maintained its 'Outperform' rating for Rocket Pharmaceuticals (RCKT) but lowered its price target from $16.00 to $15.00. The company's current stock price is $3.49, suggesting it is trading at a significant discount to the revised target. Despite some guru confidence, insider selling …

Wedbush Issues Pessimistic Forecast for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price

Wedbush has lowered its price target for Rocket Pharmaceuticals (NASDAQ:RCKT) from $16 to $15, while maintaining an "outperform" rating, indicating a significant potential upside from its current price of $3.40. The stock recently fell by 6.7%, and analyst sentiment remains mixed with a consensus …

ROCKET PHARMACEUTICALS, INC. : LEERINK PARTNERS CUTS TARGET PRICE TO $7 FROM $12

LEERINK PARTNERS has cut its target price for ROCKET PHARMACEUTICALS, INC. (RCKT.O) from $12 to $7. This information was reported by Reuters on August 11, 2026. The article advises readers that its content reflects only the author's opinion and should not be used as …

ROCKET PHARMACEUTICALS ($RCKT) Releases Q2 2026 Earnings

ROCKET PHARMACEUTICALS ($RCKT) reported its Q2 2026 earnings, missing both earnings per share and revenue estimates. The company posted an EPS of -$0.15 against an estimated $0.25, and zero revenue against an estimated $20.4 million. Insider trading data shows 12 sales and no purchases …

Rocket Pharmaceuticals: Q2 Earnings Snapshot

Rocket Pharmaceuticals Q2 Results: Net income turns positive on PRV sale

Rocket Pharmaceuticals reported a Q2 adjusted EPS of $(0.37), missing analyst estimates, but achieved a headline net income of $123.2 million due to a $178.2 million gain from a Rare Pediatric Disease Priority Review Voucher (PRV) sale. This non-recurring gain significantly boosted the company's …

Rocket Pharmaceuticals (NASDAQ:RCKT) Announces Quarterly Earnings Results, Beats Estimates By $0.22 EPS

Rocket Pharmaceuticals (NASDAQ:RCKT) announced its quarterly earnings, reporting an EPS of $1.08, which significantly surpassed analyst estimates of $0.86 by $0.22. Following the announcement, the biotechnology company's shares rose by 0.8% to $3.64. Despite a mixed analyst sentiment with a "Hold" consensus and a …

Rocket Pharmaceuticals, Inc. (RCKT) Class Action Lawsuit: Levi

Levi & Korsinsky reminds investors of the August 11, 2025 deadline to join a class action lawsuit against Rocket Pharmaceuticals, Inc. (RCKT). The lawsuit alleges that Rocket Pharmaceuticals made misleading statements and concealed material adverse facts regarding the safety and clinical trial protocol of …

Rocket Pharmaceuticals, Inc. Revenue Breakdown – BOATS:RCKTW

This article provides a brief overview of Rocket Pharmaceuticals, Inc. (RCKTW) and its financial data, specifically focusing on its revenue breakdown. It indicates that the company's financial information, including segments and regional performance, is available through TradingView, which sources data from ICE Data Services …

Form 4 Rocket Pharmaceuticals Inc For: 6 August By Investing.com

This article from Investing.com reports on a Form 4 filing for Rocket Pharmaceuticals Inc, specifically for August 6th. The content is very brief, serving primarily as an announcement of the filing and a link to view related information.

Rocket Pharma reports early safety data for Danon disease therapy

Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) announced early positive safety data for its gene therapy RP-A501 in the pivotal Phase 2 trial for Danon disease. The first three patients treated under a modified protocol showed no significant safety concerns. The company is collaborating with the FDA …

Rocket Pharmaceuticals Touts Positive Early Safety Data from Revised Genetic Therapy Trial

Rocket Pharmaceuticals (RCKT) announced positive early safety data from the first three patients in its Phase 2 trial for Danon disease, a rare genetic heart condition. The trial utilized a modified protocol with a recalibrated dose of RP-A501 and a refined immunomodulatory regimen, showing …

Rocket Pharmaceuticals Inc expected to post earnings of 37 cents a share - Earnings Preview

Rocket Pharmaceuticals Inc (RCKT) is expected to announce its earnings, with analysts projecting a loss of 37 cents per share. This preview indicates the anticipated financial performance for the upcoming earnings report. The full article from Reuters is available on TradingView for those seeking …

Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease

Rocket Pharmaceuticals has announced positive clinical safety results from the first three patients treated with RP-A501 under a modified Phase 2 protocol for Danon disease. The patients received a recalibrated dose of RP-A501 with a refined immunomodulatory regimen and exhibited no thrombotic microangiopathy (TMA), …

Rocket Pharmaceuticals (NASDAQ:RCKT) Raised to Hold at Wall Street Zen

Vanguard Portfolio Management (RCKT) reports 5.35% Rocket Pharmaceuticals ownership

Vanguard Portfolio Management has disclosed a passive ownership stake of 5.35% in Rocket Pharmaceuticals Inc. common stock, totaling 5,847,541 shares as of June 30, 2026. Vanguard maintains sole voting power over 37,508 shares and sole dispositive power over all its beneficially owned shares, with …

Rocket Pharmaceuticals Inc (RCKT) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial health analysis of Rocket Pharmaceuticals Inc (RCKT), indicating a weak financial status with a score of 5.45 out of 385 in its industry. It highlights low operating efficiency and mentions that relevant financial data for various categories like cash …

Rocket Pharmaceuticals (RCKT) to Release Quarterly Earnings on Thursday

Rocket Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:RCKTW

This page on TradingView.com provides an overview of Rocket Pharmaceuticals, Inc. (RCKTW) and focuses on its financial data, specifically the revenue breakdown. It lists various sections like financials, documents, news, and community, indicating that the detailed revenue breakdown would be accessible within the financial …

Rocket Pharmaceuticals Inc (RC

This article provides a technical analysis of Rocket Pharmaceuticals Inc (RCKT), detailing its current price momentum score, support and resistance levels, and various technical indicators. It also presents an analysis of moving averages and offers FAQs regarding technical ratings, moving averages, and technical buy/sell …

Rocket Pharmaceuticals Inc (RCKT) Institutional Confidence

Rocket Pharmaceuticals Inc (RCKT) has a high institutional confidence score of 10.00, ranking 1st in the Biotechnology & Medical Research industry. Institutional shareholding increased by 7.06% quarter-over-quarter, with the largest institutional holder being Bill Nygren | OAKMX, despite a decrease in their holdings. The …

Rocket Pharmaceuticals Inc (RCKT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Rocket Pharmaceuticals Inc (RCKT), indicating that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. It primarily serves as a placeholder for financial analysis that will be updated …

Rocket Pharmaceuticals Inc (RCKT) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of Rocket Pharmaceuticals Inc (RCKT) shareholder structure, including major shareholders and institutional holdings. It lists the top individual shareholders and their proportional stakes, categorizes shareholder types, and tracks changes in institutional shareholding over recent quarters. The report also …

RCKT|Rocket Pharmaceuticals Inc|Price:3.190|Chg%:-0.090

This article provides a comprehensive financial summary of Rocket Pharmaceuticals Inc (RCKT), including its income statement, balance sheet, and cash flow statement. It details quarterly and annual financial indicators such as EPS, Revenue, Net Profit, Debt to Assets ratio, and outlines upcoming earnings information …

Class Action Lawsuit Filed: Rocket Pharmaceuticals, Inc. (RCKT) - Join by August 11, 2025 - Contact Levi & Korsinsky

A class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (RCKT) alleging securities fraud between September 17, 2024, and May 26, 2025. The lawsuit claims the company withheld critical information about Serious Adverse Events, including patient death, in its RP-A501 clinical trial, leading …